Contrasting bone effects of temporary versus permanent IGFBP administration in rodents

Growth Hormone and IGF Research

Volumn 18, Issue 3, 2008, Pages 181-187

  Hoeflich, Andreas ^a  

^a LEIBNIZ INSTITUTE FOR FARM ANIMAL BIOLOGY FBN   (Germany)

Author keywords

Bone; IGFBPs; Local administration; Mice; Permanent; Short term; Systemic application; Temporary expression; Transgenic

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; RECOMBINANT GROWTH HORMONE; RECOMBINANT SOMATOMEDIN B; RECOMBINANT SOMATOMEDIN BINDING PROTEIN 2; RECOMBINANT SOMATOMEDIN BINDING PROTEIN 3; RECOMBINANT SOMATOMEDIN BINDING PROTEIN 4; RECOMBINANT SOMATOMEDIN BINDING PROTEIN 5; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN C; UNCLASSIFIED DRUG;

BONE DENSITY; BONE DEVELOPMENT; BONE DISEASE; BONE GROWTH; BONE MINERAL; BONE MINERALIZATION; BONE REMODELING; COMBINATION CHEMOTHERAPY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; GENE EXPRESSION; GENE OVEREXPRESSION; HETEROZYGOSITY; HOMOZYGOSITY; INTRAUTERINE GROWTH RETARDATION; LONG TERM EXPOSURE; MONOTHERAPY; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; PERINATAL MORTALITY; POSTNATAL GROWTH; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SINGLE DRUG DOSE; SYSTEMIC THERAPY; TRANSGENIC MOUSE;

ANIMALS; BONE AND BONES; GENE EXPRESSION; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; RODENTIA;

EID: 41649119751     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2008.01.003     Document Type: Review

References (45)

1. Ning Y., Schuller A.G., Bradshaw S., Rotwein P., Ludwig T., Frystyk J., and Pintar J.E. Diminished growth and enhanced glucose metabolism in triple knockout mice containing mutations of insulin-like growth factor binding protein-3, -4, and -5. Mol. Endocrinol. 20 (2006) 2173-2186
2. Conover C. Insulin-like growth factor binding proteins and bone metabolism. Am. J. Physiol. Endocrinol. Metab. (2007) Epub ahead of print
3. Mukherjee A., and Rotwein P. Insulin-like growth factor binding protein-5 in osteogenesis: facilitator or inhibitor?. Growth Horm. IGF. Res. 17 (2007) 179-185
4. Hoeflich A., Götz W., Lichanska A.M., Bielohuby M., Tonshoff B., and Kiepe D. Effects of insulin-like growth factor binding proteins in bone - a matter of cell and site. Arch. Physiol. Biochem. 113 (2007) 142-153
5. Firth S.M., and Baxter R.C. Cellular actions of the insulin-like growth factor binding proteins. Endocr. Rev. 23 (2002) 824-854
6. Mesotten D., and Van den B.G. Changes within the growth hormone/insulin-like growth factor I/IGF binding protein axis during critical illness. Endocrinol. Metab. Clin. North Am. 35 (2006) 793-805
7. Wolf E., Schneider M.R., Zhou R., Fisch T.M., Herbach N., Dahlhoff M., Wanke R., and Hoeflich A. Functional consequences of IGFBP excess - lessons from transgenic mice. Pediatr. Nephrol. 20 (2005) 269-278
8. Ben-Lagha N., Menuelle P., Seurin D., Binoux M., Lebouc Y., and Berdal A. Bone formation in the context of growth retardation induced by hIGFBP-1 overexpression in transgenic mice. Connect. Tissue Res. 43 (2002) 515-519
9. Ben-Lagha N., Seurin D., Le B.Y., Binoux M., Berdal A., Menuelle P., and Babajko S. Insulin-like growth factor binding protein (IGFBP-1) involvement in intrauterine growth retardation: study on IGFBP-1 overexpressing transgenic mice. Endocrinology 147 (2006) 4730-4737
10. Eckstein F., Pavicic T., Nedbal S., Schmidt C., Wehr U., Rambeck W., Wolf E., and Hoeflich A. Insulin-like growth factor-binding protein-2 (IGFBP-2) overexpression negatively regulates bone size and mass, but not density, in the absence and presence of growth hormone/IGF-I excess in transgenic mice. Anat. Embryol. (Berl) 206 (2002) 139-148
11. Amin S., Riggs B.L., Atkinson E.J., Oberg A.L., Melton III L.J., and Khosla S. A potentially deleterious role of IGFBP-2 on bone density in aging men and women. J. Bone Miner. Res. 19 (2004) 1075-1083
12. Sugimoto T., Nishiyama K., Kuribayashi F., and Chihara K. Serum levels of insulin-like growth factor (IGF) I, IGF-binding protein (IGFBP)-2, and IGFBP-3 in osteoporotic patients with and without spinal fractures. J. Bone Miner. Res. 12 (1997) 1272-1279
13. Reijnders C.M., Bravenboer N., Holzmann P.J., Bhoelan F., Blankenstein M.A., and Lips P. In vivo mechanical loading modulates insulin-like growth factor binding protein-2 gene expression in rat osteocytes. Calcif. Tissue Int. 80 (2007) 137-143
14. Conover C.A., Johnstone E.W., Turner R.T., Evans G.L., John Ballard F.J., Doran P.M., and Khosla S. Subcutaneous administration of insulin-like growth factor (IGF)-II/IGF binding protein-2 complex stimulates bone formation and prevents loss of bone mineral density in a rat model of disuse osteoporosis. Growth Horm. IGF Res. 12 (2002) 178-183
15. Silha J.V., Mishra S., Rosen C.J., Beamer W.G., Turner R.T., Powell D.R., and Murphy L.J. Perturbations in bone formation and resorption in insulin-like growth factor binding protein-3 transgenic mice. J. Bone Miner. Res. 18 (2003) 1834-1841
16. Bagi C., van der Meulen M., Brommage R., Rosen D., and Sommer A. The effect of systemically administered rhIGF-I/IGFBP-3 complex on cortical bone strength and structure in ovariectomized rats. Bone 16 (1995) 559-565
17. Bagi C.M., DeLeon E., Brommage R., Rosen D., and Sommer A. Treatment of ovariectomized rats with the complex of rhIGF-I/IGFBP-3 increases cortical and cancellous bone mass and improves structure in the femoral neck. Calcif. Tissue Int. 57 (1995) 40-46
18. Bagi C.M., DeLeon E., Brommage R., Adams S., Rosen D., and Sommer A. Systemic administration of rhIGF-I or rhIGF-I/IGFBP-3 increases cortical bone and lean body mass in ovariectomized rats. Bone 16 (1995) 263S-269S
19. Bagi C.M., Brommage R., DeLeon L., Adams S., Rosen D., and Sommer A. Benefit of systemically administered rhIGF-I and rhIGF-I/IGFBP-3 on cancellous bone in ovariectomized rats. J. Bone Miner. Res. 9 (1994) 1301-1312
20. Boonen S., Rosen C., Bouillon R., Sommer A., McKay M., Rosen D., Adams S., Broos P., Lenaerts J., Raus J., Vanderschueren D., and Geusens P. Musculoskeletal effects of the recombinant human IGF-I/IGF binding protein-3 complex in osteoporotic patients with proximal femoral fracture: a double-blind, placebo-controlled pilot study. J. Clin. Endocrinol. Metab. 87 (2002) 1593-1599
21. Tanaka H., Moriwake T., Matsuoka Y., Nakamura T., and Seino Y. Potential role of rhIGF-I/IGFBP-3 in maintaining skeletal mass in space. Bone 22 (1998) 145S-147S
22. Govoni K.E., Baylink D.J., and Mohan S. The multi-functional role of insulin-like growth factor binding proteins in bone. Pediatr. Nephrol. 20 (2005) 261-268
23. Zhang M., Faugere M.C., Malluche H., Rosen C.J., Chernausek S.D., and Clemens T.L. Paracrine overexpression of IGFBP-4 in osteoblasts of transgenic mice decreases bone turnover and causes global growth retardation. J. Bone Miner. Res. 18 (2003) 836-843
24. Miyakoshi N., Richman C., Qin X., Baylink D.J., and Mohan S. Effects of recombinant insulin-like growth factor-binding protein-4 on bone formation parameters in mice. Endocrinology 140 (1999) 5719-5728
25. Miyakoshi N., Qin X., Kasukawa Y., Richman C., Srivastava A.K., Baylink D.J., and Mohan S. Systemic administration of insulin-like growth factor (IGF)-binding protein-4 (IGFBP-4) increases bone formation parameters in mice by increasing IGF bioavailability via an IGFBP-4 protease-dependent mechanism. Endocrinology 142 (2001) 2641-2648
26. Lawrence J.B., Oxvig C., Overgaard M.T., Sottrup-Jensen L., Gleich G.J., Hays L.G., Yates III J.R., and Conover C.A. The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc. Natl. Acad. Sci. USA 96 (1999) 3149-3153
27. Conover C.A., Bale L.K., Overgaard M.T., Johnstone E.W., Laursen U.H., Fuchtbauer E.M., Oxvig C., and van D.J. Metalloproteinase pregnancy-associated plasma protein A is a critical growth regulatory factor during fetal development. Development 131 (2004) 1187-1194
28. Qin X., Wergedal J.E., Rehage M., Tran K., Newton J., Lam P., Baylink D.J., and Mohan S. Pregnancy-associated plasma protein-A increases osteoblast proliferation in vitro and bone formation in vivo. Endocrinology 147 (2006) 5653-5661
29. Miller B.S., Bronk J.T., Nishiyama T., Yamagiwa H., Srivastava A., Bolander M.E., and Conover C.A. Pregnancy associated plasma protein-A is necessary for expeditious fracture healing in mice. J. Endocrinol. 192 (2007) 505-513
30. Erclik M.S., and Mitchell J. Activation of the insulin-like growth factor binding protein-5 promoter by parathyroid hormone in osteosarcoma cells requires activation of an activated protein-2 element. J. Mol. Endocrinol. 34 (2005) 713-722
31. Richman C., Baylink D.J., Lang K., Dony C., and Mohan S. Recombinant human insulin-like growth factor-binding protein-5 stimulates bone formation parameters in vitro and in vivo. Endocrinology 140 (1999) 4699-4705
32. Andress D.L. IGF-binding protein-5 stimulates osteoblast activity and bone accretion in ovariectomized mice. Am. J. Physiol. Endocrinol. Metab. 281 (2001) E283-E288
33. Bauss F., Lang K., Dony C., and Kling L. The complex of recombinant human insulin-like growth factor-I (rhIGF-I) and its binding protein-5 (IGFBP-5) induces local bone formation in murine calvariae and in rat cortical bone after local or systemic administration. Growth Horm. IGF Res. 11 (2001) 1-9
34. Miyakoshi N., Richman C., Kasukawa Y., Linkhart T.A., Baylink D.J., and Mohan S. Evidence that IGF-binding protein-5 functions as a growth factor. J. Clin. Invest. 107 (2001) 73-81
35. Devlin R.D., Du Z., Buccilli V., Jorgetti V., and Canalis E. Transgenic mice overexpressing insulin-like growth factor binding protein-5 display transiently decreased osteoblastic function and osteopenia. Endocrinology 143 (2002) 3955-3962
36. Durant D., Pereira R., Stadmeyer L., and Canalis E. Transgenic mice expressing selected insulin-like growth factor-binding protein-5 fragments do not exhibit enhanced bone formation. Growth Horm. IGF Res. 14 (2004) 319-327
37. Atti E., Boskey A.L., and Canalis E. Overexpression of IGF-binding protein 5 alters mineral and matrix properties in mouse femora: an infrared imaging study. Calcif. Tissue Int. 76 (2005) 187-193
38. Salih D.A., Mohan S., Kasukawa Y., Tripathi G., Lovett F.A., Anderson N.F., Carter E.J., Wergedal J.E., Baylink D.J., and Pell J.M. Insulin-like growth factor-binding protein-5 induces a gender-related decrease in bone mineral density in transgenic mice. Endocrinology 146 (2005) 931-940
39. Overgaard M.T., Boldt H.B., Laursen L.S., Sottrup-Jensen L., Conover C.A., and Oxvig C. Pregnancy-associated plasma protein-A2 (PAPP-A2), a novel insulin-like growth factor-binding protein-5 proteinase. J. Biol. Chem. 276 (2001) 21849-21853
40. Christians J.K., Hoeflich A., and Keightley P.D. PAPPA2, an enzyme that cleaves an insulin-like growth-factor-binding protein, is a candidate gene for a quantitative trait locus affecting body size in mice. Genetics 173 (2006) 1547-1553
41. Gabbitas B., and Canalis E. Growth factor regulation of insulin-like growth factor binding protein-6 expression in osteoblasts. J. Cell Biochem. 66 (1997) 77-86
42. Gabbitas B., and Canalis E. Retinoic acid stimulates the transcription of insulin-like growth factor binding protein-6 in skeletal cells. J. Cell Physiol. 169 (1996) 15-22
43. Gabbitas B., and Canalis E. Cortisol enhances the transcription of insulin-like growth factor-binding protein-6 in cultured osteoblasts. Endocrinology 137 (1996) 1687-1692
44. Bienvenu G., Seurin D., Grellier P., Froment P., Baudrimont M., Monget P., Le B.Y., and Babajko S. Insulin-like growth factor binding protein-6 transgenic mice: postnatal growth, brain development, and reproduction abnormalities. Endocrinology 145 (2004) 2412-2420
45. Yu H.M., Liu B., Chiu S.Y., Costantini F., and Hsu W. Development of a unique system for spatiotemporal and lineage-specific gene expression in mice. Proc. Natl. Acad. Sci. USA 102 (2005) 8615-8620